IMB Dx, Inc. (KOSDAQ:461030)
2,205.00
+75.00 (3.52%)
Nov 20, 2026, 3:30 PM KST
IMB Dx Revenue
IMB Dx had revenue of 1.51B KRW in the quarter ending June 30, 2026, a decrease of -0.03%. This brings the company's total for the last twelve months to 5.60B, up 46.12% year-over-year. In the year 2025, IMB Dx had annual revenue of 5.33B with 56.40% growth. That makes IMB Dx the 40,606th largest company in the world by revenue and 2,513th in South Korea.
Revenue (ttm)
5.60B
Revenue Growth
+46.12%
P/S Ratio
5.52
Revenue / Employee
n/a
Employees
n/a
Market Cap
30.91B
Revenue by Segment
Fiscal year ended Dec 31, 2024 See the full IMB Dx breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.33B | 1.92B | 56.40% |
| Dec 31, 2024 | 3.41B | -619.97M | -15.40% |
| Dec 31, 2023 | 4.03B | 1.40B | 53.42% |
| Dec 31, 2022 | 2.62B | 1.39B | 113.34% |
| Dec 31, 2021 | 1.23B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HLB Therapeutics | 64.45B |
| ORIENT BIO | 59.09B |
| Amicogen | 46.69B |
| Prestige BioPharma | 26.07B |
| GeneOne Life Science | 9.07B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| MedPacto | 4.80B |